Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

News SummaryMost relevantAll newsSector news 

CVS Caremark 4th-Quarter Profit Up 2.6% on Higher Sales

02/06/2013 | 08:59am US/Eastern

--Debt refinancing costs weigh on bottom line, but sales broadly higher

--PBM, retail sales each rise, helping CVS report better-than-expected results

--Same-store sales growth exceeds monthly data posted by Walgreen, Rite Aid

(Updates with CEO interview comments, additional background and the latest stock quote, beginning in the first paragraph.)

   By John Kell 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as debt refinancing costs weighed on the bottom line, somewhat masking a strong performance for the company's pharmacy-benefits-management business and higher retail sales.

The drugstore retailer and PBM has now reported better-than-expected adjusted earnings for four consecutive quarters. Results in the fourth quarter were led by the PBM business, which saw revenue rise 17% to $18.6 billion, aided by new clients added to the network during the 2012 PBM selling season, higher drug costs and growth in the Medicare Part D program.

On the retail side, the top line jumped 5.1% to $16.3 billion as same-store sales grew 4%, growth that exceeds the monthly sales data posted by rivals Walgreen Co. (>> Walgreen Company) and Rite Aid Corp. (>> Rite Aid Corporation) in late 2012. Prescription volume growth was healthy, aided by client wins after Walgreen's contract dispute last year with fellow PBM Express Scripts Holding Co. (>> Express Scripts Holding Co) and stronger demand for flu-related prescriptions.

But CVS said pharmacy same-store sales were stung by higher usage of low-priced generics, which hurts the top line for drug store chains, though those products have a mixed benefit as they command higher margins.

An active flu season has helped drugstore chains somewhat mitigate the top-line dent caused by higher generic penetration, as consumers seek out vaccinations, order prescriptions and buy over-the-counter cough-and-cold medications. CVS Chief Executive Larry Merlo told Dow Jones Newswires that the company saw a "significant uptick" in flu activity by mid-December and strong demand through most of January.

Mr. Merlo said over the past two weeks, CVS has seen the severity of flu cases moderate. Still, the company has administered about 4.8 million flu shots so far this season, above last year's level.

Overall, CVS reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-related costs and other items, adjusted earnings from continuing operations were $1.14 in the latest quarter. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Gross margin expanded to 20.1% from 19.6%.

For the year, CVS now sees adjusted earnings from continuing operations of $3.86 to $4, a view that was lifted by two cents to reflect the debt refinancing.

CVS will face some lofty comparisons in 2013, due to strong demand for generics, particularly in the first half of the year. And after Walgreen inked a contract agreement with Express Scripts starting in September, the company has had some success winning back some customers it lost to competitors during the months-long spat, resulting in some lost business for CVS.

Shares were up 1.5% to $52.50 in premarket trading.

--Tess Stynes contributed to this article

Write to John Kell at john.kell@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

React to this article
Latest news on CVS HEALTH CORP
11/23 CVS HEALTH : pharmacy Helps Shoppers Enjoy a Healthier, Less Stressful Holiday S..
11/23 CVS HEALTH : Announces Formulary and Therapy Strategy for PCSK9 Inhibitors
11/23DJCVS Chooses New Cholesterol Drug for Caremark
11/23 CVS HEALTH : Achieves Perfect Score on 14th Annual Scorecard on LGBT Workplace E..
11/23DJCVS Chooses Repatha as New Cholesterol Drug for Caremark
11/19 CVS HEALTH : Research Institute Study Demonstrates Impact of Prescription Refill..
11/19 CVS HEALTH : Achieves Perfect Score on 14th Annual Scorecard on LGBT Workplace E..
11/19DJTarget's Apparel, Online Sales Come Under Added Pressure
11/18 Target's online sales growth slows; margins pressured
11/18DJTarget Reports Slower Sales Growth--3rd Update
News chart
Full-screen chart
Income Statement Evolution
More Financials